Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine

Nat Commun. 2022 Jun 16;13(1):3466. doi: 10.1038/s41467-022-31142-5.

Abstract

RNA-based vaccines against SARS-CoV-2 have proven critical to limiting COVID-19 disease severity and spread. Cellular mechanisms driving antigen-specific responses to these vaccines, however, remain uncertain. Here we identify and characterize antigen-specific cells and antibody responses to the RNA vaccine BNT162b2 using multiple single-cell technologies for in depth analysis of longitudinal samples from a cohort of healthy participants. Mass cytometry and unbiased machine learning pinpoint an expanding, population of antigen-specific memory CD4+ and CD8+ T cells with characteristics of follicular or peripheral helper cells. B cell receptor sequencing suggest progression from IgM, with apparent cross-reactivity to endemic coronaviruses, to SARS-CoV-2-specific IgA and IgG memory B cells and plasmablasts. Responding lymphocyte populations correlate with eventual SARS-CoV-2 IgG, and a participant lacking these cell populations failed to sustain SARS-CoV-2-specific antibodies and experienced breakthrough infection. These integrated proteomic and genomic platforms identify an antigen-specific cellular basis of RNA vaccine-based immunity.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antibodies, Viral
  • BNT162 Vaccine
  • CD8-Positive T-Lymphocytes
  • COVID-19 Vaccines*
  • COVID-19* / prevention & control
  • Humans
  • Immunoglobulin G
  • Proteomics
  • RNA, Viral / genetics
  • SARS-CoV-2
  • Vaccines, Synthetic
  • mRNA Vaccines

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines
  • Immunoglobulin G
  • RNA, Viral
  • Vaccines, Synthetic
  • mRNA Vaccines
  • BNT162 Vaccine